Daiwa Securities Group Inc. - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 94 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$61
-29.1%
4,7620.0%0.00%
-100.0%
Q2 2023$86
+4200.0%
4,762
+3563.1%
0.00%
Q1 2023$2
-33.3%
1300.0%0.00%
Q4 2022$3
-99.7%
130
+38.3%
0.00%
Q3 2022$1,0000.0%940.0%0.00%
Q2 2022$1,0000.0%940.0%0.00%
Q1 2022$1,000
-50.0%
940.0%0.00%
Q4 2021$2,000940.00%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q1 2023
NameSharesValueWeighting ↓
Octagon Capital Advisors LP 377,777$15,659,0005.43%
BVF INC/IL 1,106,070$45,847,0001.80%
Eagle Health Investments LP 50,000$2,073,0001.33%
Ally Bridge Group (NY) LLC 150,000$6,218,0001.07%
Casdin Capital, LLC 780,555$32,354,0000.96%
VIKING GLOBAL INVESTORS LP 3,937,914$163,227,0000.45%
Pinz Capital Management, LP 19,900$825,0000.38%
ArrowMark Colorado Holdings LLC 1,063,744$44,092,0000.34%
Perceptive Advisors 600,256$24,881,0000.27%
ACUTA CAPITAL PARTNERS, LLC 20,000$829,0000.23%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders